Opinion – anti-infectives: Where will new antibiotics come from?

Nature Reviews Microbiology

Volumn 1, Issue 1, 2003, Pages 65-70

  Walsh, Christopher ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BIOLOGICAL PRODUCT;

ANIMAL; ARTICLE; BACTERIAL INFECTION; BACTERIUM; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; GENETICS; HISTORY; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BIOLOGICAL PRODUCTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0345839252     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro727     Document Type: Article

References (32)

1. Thornsberry, C. et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin. Infect. Dis. 34, S4-S16 (2002).
2. Palumbi, S. R. Humans as the world's greatest evolutionary force. Science 293, 1786-1790 (2001).
3. Walsh, C. T. Antibiotics: Actions, Origins, Resistance. (ASM Press, Washington DC, USA, 2003).
4. Coates, A., Hu, Y, Bax, R. & Page, C. The future challenges facing the development of new antimicrobial drugs. Nature Rev. Drug Discov. 1, 895-910 (2002).
5. Tally, F. P. & DeBruin, M. F. Development of daptomycin for gram-positive infections. J. Antimicrob. Chemother. 46, 523-526 (2000).
6. MacNeil, I. A. et al. Expression and isolation of small molecules from soil DNA libraries. J. Mol. Microbiol. Biotechnol. 3, 301-308 (2001).
7. Khosla, C. Harnessing the biosynthetic potential of modular polyketide synthases. Chem. Rev. 97, 2577-2590 (1997).
8. Cane, D. E., Walsh, C. T. & Khosla, C. Harnessing the biosynthetic code; combinations, permutations, and mutations. Science 282, 63-68 (1998).
9. Howe, R. A. & Spencer, R. C. Cotrimoxazole, rationale for re-examining its indications for use. Drug Saf. 14, 213-218 (1996).
10. Scholar, E. M. & Pratt, W. B. The Antimicrobial Drugs 2nd edn (Oxford Univ. Press, New York, 2000).
11. Maxwell, A. DNA Gyrase as a drug target. Trends Microbiol 5, 102-109 (1997).
12. Arya, P D., Chou, T. H. & Baek, M. G. Diversity-based organic synthesis in the era of genomics and proteomics. Angew. Chem. Int. Ed. 40, 339-346 (2001).
13. Arya, P D., Joseph, R. & Chou, D. T. Toward high-throughput synthesis of complex natural product-like compounds in the genomics and proteomics age. Chem. Biol. 9, 145-146 (2002).
14. Schreiber, S. L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287, 1964-1969 (2000).
15. Teague, S., Leason, D., Oprea, P. D. & Davis, T. The design of leadlike combinatorial libraries Angew. Chem. Int. Ed. 38, 3743-3748 (1999).
16. McDaniel, R. A. et al. Multiple genetic modifications of the erythromycin polyketide synthase to produce a library of "unnatural" natural products. Proc. Natl Acad. Sci. USA 96, 1846-1851 (1999).
17. Walsh, C. T. Combinatorial biosynthesis of antibiotics: challenges and opportunities. Chem. Biochem. 3, 124-134 (2002).
18. Carter, A. P. et al. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 407, 340-348 (2000).
19. Hansen, J. L. et al. The structures of four macrolide antibiotics bound to the large ribosomal subunit. Mol. Cell 10, 117-128 (2002).
20. Pioletti, M. et al. Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine, and IF3. EMBO J. 20, 1829-1839 (2001).
21. Schlunzen, F. R. et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 413, 814-821 (2001).
22. Peterson, T. D. et al. The comprehensive microbial resource. Nucl. Acids Res. 29, 123-125 (2001).
23. Ji, Y. B. et al. Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science 293, 2266-2269 (2001).
24. McDevitt, D. & Rosenberg, M. Exploiting genomics to discover new antibiotics. Trends Microbiol. 9, 611-617 (2001).
25. Ye, X. Y. et al. Better substrates for bacterial transglycosylases. J. Am. Chem. Soc. 123, 3155-3156 (2001).
26. Yusupov, M. M. et al. Crystal structure of the ribosome at 5.5-A resolution. Science 292, 883-896 (2001).
27. Navarre, W. W. & Schneewind, O. Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol. Mol. Biol. Rev. 63, 174-229 (1999).
28. Pallen, M. J., Lam, A. C., Antonio, M. & Dunbar, K. An embarrassment of sortases-a richness of substrates? Trends Microbiol. 9, 97-102 (2001).
29. Rohdich, F., Kis, K., Bacher, A. & Eisenreich, W. The non-mevalonate pathway of isoprenoids: genes, enzymes, and intermediates. Curr. Opin. Chem. Biol. 5, 535-540 (2001).
30. Murray, B. E. Vancomcyin-resistant enterococcal infections New Eng. J. Med. 342, 710-721 (2000).
31. Bonhoeffer, S., Lipsitch, M. & Levin, B. R. Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl Acad. Sci. USA 94, 12106-12111 (1997).
32. Shlaes, D. et al. Guidelines for the prevention of antimicrobial resistance in hospitals. Clin. Infect. Dis. 25, 584-599 (1997).